TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Zydus Lifesciences Ltd.

ZYDUSLIFE on NSE · 19 Nov 2026

NIFTY 500 F&O

1,202.90 ▲ +0.07 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance

Guidance tracker

What ZYDUSLIFE guided, and what came next

FiledWhat the filing saysNext results: profit YoYRevenueMove on the day
07 Nov 2026Zydus Lifesciences filed the transcript of its Q2 FY27 post-results earnings call held on November 4, 2026. Management said consolidated revenue was ₹79.1 billion, up 29% year-on-year, with EBITDA of ₹18.9 billion (24% margin) and net profit of ₹9.3 billion; net debt to EBITDA was 0.62 times. Management said India... NSE copy No results filed since
18 Aug 2026Zydus Lifesciences filed the transcript of its Q1 FY27 post-results earnings call held on August 11, 2026. Management said consolidated revenue was ₹80.2 billion, up 22% year-on-year, with EBITDA of ₹19.3 billion (EBITDA margin 24.1%) and net profit of ₹9.4 billion; net debt to EBITDA was 0.7 times as on June 30,... NSE copy -26.5 %+29.2 %+0.4 %
24 May 2026Zydus Lifesciences filed the transcript of its Q4 FY26 post-results earnings call held on May 19, 2026. Management said FY26 consolidated revenue was ₹271.5 billion, up 17% year-on-year, with consolidated EBITDA of ₹84.8 billion (up 20%) and an EBITDA margin of 31.2%; net profit adjusted for exceptional items was... NSE copy -35.9 %+22.0 %+1.2 %
15 Feb 2026Zydus Lifesciences filed the transcript of its Q3 FY26 post-results earnings call held on February 10, 2026. Management reported Q3 consolidated revenue of ₹68.6 billion, up 30% year-on-year, and EBITDA of ₹18.2 billion, up 31%, with a 26.5% EBITDA margin. Adjusted net profit for the quarter was ₹11.1 billion, up... NSE copy +1647.9 %+16.2 %+2.2 %
13 Nov 2025Zydus Lifesciences filed the transcript of its Q2 FY26 post-results earnings call held on November 6, 2025. Management said consolidated revenue was Rs. 61.2 billion, up 17% year-on-year, with EBITDA of Rs. 20.2 billion (margin 32.9%) and net profit of Rs. 12.6 billion, up 38% year-on-year. Management said US... NSE copy +1.8 %+30.3 %-3.9 %
20 Aug 2025Zydus Lifesciences filed the transcript of its Q1 FY26 post-results earnings call held on August 12, 2025, under Regulations 30 and 46(2)(oa) of the Listing Regulations. Management reported consolidated revenue of ₹65.7 billion, up 6% year-on-year, EBITDA of ₹20.9 billion at a 31.8% margin, and net profit of ₹14.7... NSE copy +38.2 %+16.9 %+0.8 %
24 Jun 2025Zydus Lifesciences filed its June 2025 investor presentation, to be used at investor conferences between June 25 and June 27, 2025. The presentation gives FY25 revenues of US$2.75 bn (Rs 225.7 bn) and EBITDA of US$835 mn (30.4% margin), with R&D spend of US$219 mn (8.0% of revenues). Sales split by segment: India... NSE copy +3.3 %+5.9 %+3.4 %
11 Feb 2025Zydus Lifesciences filed the transcript of its Q3 FY25 post-results earnings call held on February 5, 2025. Management reported consolidated revenue of ₹52.7 billion, up 17% year-on-year, and EBITDA of ₹13.9 billion, up 26%, with reported EBITDA margin of 26.3% versus 24.5%. Net profit for the quarter was ₹10.2... NSE copy +20.1 %+18.0 %+0.7 %
19 Nov 2024Zydus Lifesciences filed the transcript of its Q2 FY25 post-results earnings call held on November 12, 2024, under SEBI Listing Regulations 30 and 46(2)(oa). Management said consolidated revenue was Rs.52.4 bn, up 20% year on year, and EBITDA was Rs.14.6 bn, up 28%, with EBITDA margin at 27.9%, up 170 basis points.... NSE copy +33.3 %+17.0 %+3.2 %

Filings tagged as guidance, newest first (9 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.

Governance

Management, auditors, ratings and legal matters

FiledKindWhat the filing says
07 Nov 2026Legal or regulatoryZydus Lifesciences filed the transcript of its Q2 FY27 post-results earnings call held on November 4, 2026. Management said consolidated revenue was ₹79.1 billion, up 29% year-on-year, with EBITDA of ₹18.9 billion (24% margin) and net profit of ₹9.3 billion; net debt to EBITDA was 0.62 times. Management said India... NSE copy
04 Nov 2026Legal or regulatoryZydus Lifesciences filed its investor presentation on unaudited results for the quarter and half year ended September 30, 2026 (Q2 FY27). Total revenues from operations were Rs. 79,096 mn, up 29% YoY; net profit was Rs. 9,255 mn, and EBITDA was Rs. 18,945 mn at a 24.0% margin. Organic capex for the quarter was Rs.... NSE copy
04 Nov 2026Legal or regulatory, Management changeZydus Lifesciences intimated under Regulation 30 of the Listing Regulations that its Board, at its meeting held on November 4, 2026, approved the appointment of Walker Chandiok & Co LLP (Firm Registration No. 001076N/N500013) as statutory auditors. The appointment replaces Deloitte Haskins and Sells LLP, which... NSE copy
11 Sep 2026Credit ratingZydus Lifesciences intimated under Regulation 30 that CRISIL Ratings Limited reviewed and reaffirmed its credit ratings by letters dated September 10, 2026. Bank facilities of Rs. 4,724 crore: long-term rating CRISIL AAA/Stable and short-term rating CRISIL A1+, both reaffirmed. Commercial papers of Rs. 200 crore... NSE copy
18 Aug 2026Legal or regulatoryZydus Lifesciences filed the transcript of its Q1 FY27 post-results earnings call held on August 11, 2026. Management said consolidated revenue was ₹80.2 billion, up 22% year-on-year, with EBITDA of ₹19.3 billion (EBITDA margin 24.1%) and net profit of ₹9.4 billion; net debt to EBITDA was 0.7 times as on June 30,... NSE copy
11 Aug 2026Legal or regulatoryZydus Lifesciences filed its Q1 FY27 earnings investor presentation (quarter ended June 30, 2026) under Regulation 30 read with Regulation 46 of the Listing Regulations. Total revenues from operations were Rs. 80,170 mn, up 22% YoY; EBITDA was Rs. 19,294 mn with a 24.1% margin, down 770 bps YoY; reported PAT was... NSE copy
01 Jun 2026Legal or regulatoryZydus Lifesciences submitted a restated Letter of Offer dated May 31, 2026 for its buyback; only paragraph 19.5.4 was restated and all other terms are unchanged. The buyback covers up to 87,30,158 fully paid-up equity shares (face value INR 1) at INR 1,260 per share through the tender offer route, for an aggregate... NSE copy
31 May 2026Legal or regulatoryZydus Lifesciences filed the letter of offer dated May 31, 2026 for a buyback of not exceeding 87,30,158 equity shares (face value INR 1) at INR 1,260 per share, aggregate not exceeding INR 1,100 crore, via tender offer route. Record date for the buyback is May 29, 2026; the buyback opens on June 4, 2026 and closes... NSE copy
24 May 2026Legal or regulatoryZydus Lifesciences filed the transcript of its Q4 FY26 post-results earnings call held on May 19, 2026. Management said FY26 consolidated revenue was ₹271.5 billion, up 17% year-on-year, with consolidated EBITDA of ₹84.8 billion (up 20%) and an EBITDA margin of 31.2%; net profit adjusted for exceptional items was... NSE copy
19 May 2026Legal or regulatoryZydus Lifesciences' board approved a buyback of up to 95,65,217 fully paid-up equity shares (face value INR 1 each), about 0.95% of paid-up equity capital as on March 31, 2026, at INR 1,150 per share. The aggregate buyback size is not exceeding INR 1,100,00,00,000 (INR 1,100 crore), excluding transaction costs, and... NSE copy
15 Feb 2026Legal or regulatoryZydus Lifesciences filed the transcript of its Q3 FY26 post-results earnings call held on February 10, 2026. Management reported Q3 consolidated revenue of ₹68.6 billion, up 30% year-on-year, and EBITDA of ₹18.2 billion, up 31%, with a 26.5% EBITDA margin. Adjusted net profit for the quarter was ₹11.1 billion, up... NSE copy
09 Feb 2026Legal or regulatoryZydus Lifesciences filed an investor presentation on its unaudited results for the quarter and nine months ended December 31, 2025 (Q3 & 9M FY26), dated February 9, 2026. Q3 FY26 total revenues from operations were Rs. 68,645 mn, up 30% YoY; EBITDA was Rs. 11,109 mn, up 9% YoY, with EBITDA margin at 26.5%, up 20... NSE copy
09 Feb 2026Legal or regulatoryBoard of Zydus Lifesciences approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, on February 9, 2026. Standalone revenue from operations for Q3 FY26 was INR 22,836 million, down from INR 25,159 million a year earlier; net profit was INR 2,965... NSE copy
06 Nov 2025Legal or regulatoryZydus Lifesciences filed its investor presentation on unaudited results for the quarter and half year ended September 30, 2025 (Q2 & H1 FY26). Total revenues from operations were Rs. 61,232 mn in Q2 FY26, up 17% YoY; EBITDA was Rs. 20,158 mn with a margin of 32.9%, up 500 bps YoY; net profit was Rs. 12,586 mn, up... NSE copy
12 Aug 2025Legal or regulatoryZydus Lifesciences filed its Q1 FY26 earnings investor presentation (quarter ended June 30, 2025) on August 12, 2025. Total revenues from operations were Rs. 65,737 mn, up 6% YoY; EBITDA was Rs. 14,668 mn with a 31.8% margin, flat YoY; net profit (PAT ex. exceptional) was Rs. 9,112 mn... [see note] Net cash stood... NSE copy
27 May 2025Legal or regulatoryZydus Lifesciences filed the transcript of its Q4 FY25 post-results earnings call held on May 20, 2025. Management said FY25 consolidated revenue was Rs 232.4 billion, up 19% year-on-year, with operating margin of 30.4% (up 290 bps) and EBITDA up 31% to Rs 70.6 billion. Management reported FY25 adjusted net profit... NSE copy
20 May 2025Legal or regulatoryZydus Lifesciences filed its investor presentation on audited results for Q4 and full year FY25 (quarter/year ended March 31, 2025), dated May 20, 2025. Q4 FY25 total revenues from operations were Rs. 65,279 mn, up 18% YoY; full-year FY25 revenues were Rs. 2,32,415 mn versus Rs. 1,95,474 mn in FY24. Q4 FY25 EBITDA... NSE copy
11 Mar 2025Legal or regulatoryZydus Lifesciences' board approved entering agreements to acquire a controlling 85.6% stake in Amplitude Surgical SA, France (listed on Euronext Paris) at EUR 6.25 per share, for a consideration of EUR 256.8 million. Post-closing, the company would make a mandatory simplified cash tender offer for the remaining... NSE copy
30 Dec 2024Credit ratingZydus Lifesciences intimated that CRISIL Ratings reviewed and reaffirmed its credit ratings on December 30, 2024. Bank facilities of Rs. 4,724 crore: long-term rating CRISIL AAA/Stable (reaffirmed) and short-term rating CRISIL A1+ (reaffirmed). Commercial papers of Rs. 200 crore: CRISIL A1+ (reaffirmed); no... NSE copy

Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (19 in all). A list of what was filed, not a judgement of the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in